# US 2003/0215843 A1 · Screening of a novel hepatic syndrome and its uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215843 A1
- Document ID: US20030215843A1
- Status: Published application
- Kind: A1
- Application number: 10/360,705
- Filed: 2003-02-10
- Published: 2003-11-20
- Earliest claimed: 2000-08-08
- Assignees: Assistance Publique-Hopitaux de Paris
- Inventors: Raoul Poupon; Brigitte Hermelin; Olivier Rosmorduc
- Web page: https://patentgrep.com/patent/US20030215843A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns methods of screening for a hepatic syndrome occurring in the young adult and associating cholesterol biliary microlithiasis, intrahepatic cholestasis and several mutations of the MDR3 gene. The invention is also directed to methods for the treatment of said syndrome. The hepatic syndrome screening methods comprise detecting, from a nucleic acid sample extracted from peripheral blood mononucleate cells, heterozygous mutations of the MDR3 gene and/or homozygous mutations of the MDR3 gene that do not eliminate the expression of the protein expressed by the MDR3 gene, which has phosphatidylcholine carrier activity, in adult subjects associating cholesterol biliary microlithiasis and intrahepatic cholestasis.

## Claims

### Claim 1

A method of screening for a hepatic syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis, wherein said method comprises detecting in a sample of nucleic acid extracted from peripheral blood mononuclear cells of a subject, at least one heterozygous mutation of the MDR3 gene or at least one homozygous mutation of the MDR3 gene, or both, wherein said mutation or mutations do not destroy the expression of the protein expressed by said gene with phosphatidylcholine transporter activity, wherein the presence of said mutation or mutations in the nucleic acid of said subject is an indicator of susceptibility to said hepatic syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of said mutations is located within any one or all of the exons selected from the group consisting of exon 6, exon 9 and exon 12.

### Claim 3 (depends on 2)

The method of claim 2, wherein at least one of said mutations is selected from the group consisting of a mutation in exon 6 at nucleotide 523, a mutation in exon 9 at nucleotide 959 and a mutation in exon 12 at nucleotide 1327.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mutation located at nucleotide 523 is a heterozygous missense mutation A/G (ACG/GCG), leading to the amino acid mutation T175V, the mutation located at nucleotide 959 is a homozygous missense mutation C/T (TCC/TTC), leading to the amino acid mutation S320F, and the mutation located at nucleotide 1327 corresponds to the insertion of an adenine (1327insA).

### Claim 5 (depends on 1)

The method of claim 1, wherein said MDR3 gene mutation or mutations are located in at least one of the following exons: 4, 5, 6, 8, 9, 10, 12, 14, 15, 16, 17, 18, 19, 23 or 26.

### Claim 6 (depends on 5)

The method of claim 5, wherein said mutation or mutations are located in at least one of exons 9, 10, 12, 14, 15, 17 or 18.

### Claim 7 (depends on 5)

The method of claim 5, wherein said method comprises the detection of a mutation or mutations selected from the group consisting of:
a) a mutation in exon 4 at nucleotide 175,
b) a mutation in exon 6 at nucleotide 495, 504 or 523,
c) a mutation in exon 8 at nucleotide 711,
d) a mutation in exon 9 at nucleotide 902 or 959,
e) a mutation in exon 10 at nucleotides 1007-1015 (insertion or deletion),
f) a mutation in exon 12 at nucleotide 1327,
g) a mutaton in exon 14 at nucleotide 1584,
h) a mutation in exon 15 at nucleotide 1772,
i) a mutation in exon 16 at nucleotide 1954,
j) a mutation in exon 17 at nucleotide 1973,
k) a mutation in exon 18 at nucleotides 2270-2273 (insertion),
l) a mutation in exon 19 at nucleotide 2363,
m) a mutation in exon 23 at nucleotide 2800 and
n) a mutation in exon 26 at nucleotide 3481.

### Claim 8 (depends on 5)

The method of claim 5, wherein said method comprises:
a) amplifying nucleic acid extracted from peripheral blood mononuclear cells, using at least one primer selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:13 and SEQ ID NO:15 through SEQ ID NO:66, and
b) detecting the presence of at least one of said mutations in the amplified product of step (a).

### Claim 9 (depends on 8)

The method of claim 8, wherein the first amplification step consists of direct PCR amplification of at least one of exons 6, 9 and 12 of the genomic DNA with the following primers, located in the flanking intronic regions:
a) primers SEQ ID NO:1 and SEQ ID NO:2, which make it possible to amplify a 321 bp fragment covering exon 6,
b) primers SEQ ID NO:3 and SEQ ID NO:4, which make it possible to amplify a 210 bp fragment covering exon 9, and
c) primers SEQ ID NO:5 and SEQ ID NO:6, which make it possible to amplify a 154 bp fragment covering exon 12.

### Claim 10 (depends on 8)

The method of claim 8, wherein the first amplification step consists of RT-PCR amplification of mRNAs by two overlapping PCRs, using two pairs of primers selected from the group consisting of the following pairs:
a) SEQ ID NO:7 and SEQ ID NO:8
b) SEQ ID NO:9 and SEQ ID NO: 10
c) SEQ ID NO:11 and SEQ ID NO:10
d) SEQ ID NO:12 and SEQ ID NO:10, and
e) SEQ ID NO:13 and SEQ ID NO: 10.

### Claim 11 (depends on 8)

The method of claim 8, wherein the first amplification step consists of direct PCR amplification of at least one of exons 6, 9, 10, 12, 14, 15, 17, 18, 19, 23, and 26 and further of at least one of exons 4, 5, 8 and 16 of the genomic DNA with the primers, located in the flanking intronic regions, wherein said primers are selected from the group consisting of any one or more of SEQ ID NO:15 through SEQ ID NO:66.

### Claim 12 (depends on 8)

The method of claim 8, wherein the second step of detection of the presence of at least one of said mutations using the amplified fragment is carried out using one of the following methods: sequencing, enzyme restriction or techniques of the PCR/PCR/LDR type.

### Claim 13 (depends on 9)

The method of claim 9, wherein the detection step is carried out by digestion of the 210 bp amplification fragment with the HinfI enzyme.

### Claim 14 (depends on 9)

The method of claim 9, wherein the detection step is carried out by digestion of the 210 bp amplification fragment with the BamHI enzyme.

### Claim 15 (depends on 1)

The method of claim 1, wherein said subject is determined to be at risk of developing cholesterol lithiasis or having unexplained hepatic biological abnormalities.

### Claim 16

A method of screening for a syndrome associated with one or more of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis, wherein said method comprises contacting a nucleic acid sample extracted from peripheral blood mononuclear cells of a subject with primers selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:13 and SEQ ID NO:15 through SEQ ID NO:66, wherein said contacting results in the identification of at least one mutation of the MDR3 gene and wherein said identification is an indicator of suceptibility to developing said syndrome.

### Claim 17

A kit for the screening of a hepatic syndrome associated with at least one mutation of the MDR3 gene, wherein said kit comprises at least two primers selected from the group consisting of SEQ ID NO:1 through SEQ ID NO:13 and SEQ ID NO:15 to SEQ ID NO:66.

### Claim 18

A kit for evaluating a population at risk of developing a hepatic syndrome associated with at least one mutation of the MDR3 gene comprising, in addition to two primers selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:13 or SEQ ID NO:15 to SEQ ID NO:66, reagents for assaying cholesterol and bile phospholipids.

### Claim 19

A method of treating a patient having a syndrome associated with at least one of intrahepatic hyperechoic foci with or without intrahepatic sludge or microlithiasis, cholesterol microcholelithiasis and intrahepatic cholestasis and at least one mutation of the MDR3 gene, wherein said method comprises administering to said patient a pharmaceutical composition comprising ursodeoxycholic acid.

### Claim 20 (depends on 1)

The method of claim 1, wherein said subject is a young adult.
